Early Data Show Positive Activity of Iberdomide Against Heavily Treated MM
Interim data from an ongoing Phase 1/2 clinical trial show that Celgene’s investigational therapy iberdomide (CC-220), used in combination with dexamethasone, is safe and…
Myeloma
AMG 420 Immunotherapy Effective in Difficult-to-treat Multiple Myeloma, Early Study Results Show
The investigational immunotherapy AMG 420 lessened tumor burden and led to cancer disappearing in half of the patients with relapsed or refractory multiple…
Clinical Trial Results Suggest Isatuximab Improves Survival in People with RRMM
Isatuximab, a potential therapeutic antibody, can improve survival in relapsed/refractory multiple myeloma patients being given a standard treatment consisting of Pomalyst (pomalidomide) and…
Similar Efficacy and Safety Seen Between Under-the-Skin Formulation and Intravenous Darzalex for Myeloma, Phase 3 Trial Shows
An under-the-skin formulation of daratumumab is as effective as its intravenous delivery — marketed as Darzalex — at easing tumor burden and has comparable…
FDA Grants Priority Review to Darzalex Combo for Transplant-eligible Patients
The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) of Darzalex (daratumumab)…
CAR T-Cell Candidate bb2121 Shows Promise in Heavily Pre-treated Myeloma, Interim Data Show
The candidate CAR-T cell therapy bb2121 showed a favorable safety profile and eliminated traces…
Pivotal OPTIMISMM Trial Shows Benefits of Pomalyst Triple Combo Therapy
Treatment with Pomalyst (pomalidomide) in combination with Velcade (bortezomib) and dexamethasone prolongs survival without disease worsening…
Open Enrollment for Phase 1 Trial Testing CS1-CAR T-Cell Therapy for Hard-to-Treat Myeloma
A Phase 1 clinical trial is recruiting patients with hard-to treat or relapsed multiple myeloma to evaluate Mustang Bio’s investigational autologous (patient-derived)…
Oncopeptides Prepares NDA for Accelerated Approval of Ygalo as Treatment for Refractory Multiple Myeloma
Oncopeptides is preparing to submit a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) to seek accelerated…
Revlimid Becomes Option for First-line Multiple Myeloma Treatment in England
The National Institute for Health and Care Excellence (NICE) in England has recommended treatment with Revlimid (lenalidomide) and dexamethasone for multiple myeloma…
